On August 28, 2024, Novo Nordisk A/S announced that board members and executives, including Executive Vice President Douglas Langa, purchased a total of 16,789 ADRs at prices of DKK 904.41 and DKK 904.35, amounting to DKK 15,183.93 in total. This filing fulfills the regulatory requirement for disclosure of trades by management and their associates.